These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12645447)

  • 1. Spasticity in multiple sclerosis.
    Barnes MP; Kent RM; Semlyen JK; McMullen KM
    Neurorehabil Neural Repair; 2003 Mar; 17(1):66-70. PubMed ID: 12645447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.
    Rekand T; Grønning M
    J Rehabil Med; 2011 May; 43(6):511-4. PubMed ID: 21533331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-spasticity agents for multiple sclerosis.
    Shakespeare DT; Boggild M; Young C
    Cochrane Database Syst Rev; 2003; (4):CD001332. PubMed ID: 14583932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-spasticity agents for multiple sclerosis.
    Shakespeare DT; Boggild M; Young C
    Cochrane Database Syst Rev; 2001; (4):CD001332. PubMed ID: 11687107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-spasticity agents for multiple sclerosis.
    Shakespeare DT; Young CA; Boggild M
    Cochrane Database Syst Rev; 2000; 2003(4):CD001332. PubMed ID: 11034714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug treatments for spasticity.
    Yelnik AP; Simon O; Bensmail D; Chaleat-Valayer E; Decq P; Dehail P; Quentin V; Marque P; Parratte B; Pellas F; Rousseaux M; Trocello JM; Uzzan M; Dumarcet N;
    Ann Phys Rehabil Med; 2009 Dec; 52(10):746-56. PubMed ID: 19892619
    [No Abstract]   [Full Text] [Related]  

  • 7. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.
    Cutter NC; Scott DD; Johnson JC; Whiteneck G
    Arch Phys Med Rehabil; 2000 Feb; 81(2):164-9. PubMed ID: 10668769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis.
    Anwar K; Barnes MP
    NeuroRehabilitation; 2009; 24(4):333-40. PubMed ID: 19597271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study.
    Smith KA; Piehl F; Olsson T; Alfredsson L; Hillert J; Kockum I; Stridh P; Montgomery S
    J Neurol Neurosurg Psychiatry; 2023 May; 94(5):337-348. PubMed ID: 36539267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients.
    Ben Smail D; Peskine A; Roche N; Mailhan L; Thiébaut I; Bussel B
    Mult Scler; 2006 Feb; 12(1):101-3. PubMed ID: 16459726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin should be first-line treatment for poststroke spasticity.
    Sheean G
    J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):359. PubMed ID: 19289475
    [No Abstract]   [Full Text] [Related]  

  • 13. Spasticity.
    Rush R; Kumbhare D
    CMAJ; 2015 Apr; 187(6):436. PubMed ID: 25404397
    [No Abstract]   [Full Text] [Related]  

  • 14. Intrathecal baclofen for muscle spasticity and pain--two case reports.
    Al Khudhairi D; Rababa A; Saddiqui MN
    Middle East J Anaesthesiol; 2006 Jun; 18(5):971-6. PubMed ID: 17094537
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of hydrotherapy for the management of spasticity.
    Kesiktas N; Paker N; Erdogan N; Gülsen G; Biçki D; Yilmaz H
    Neurorehabil Neural Repair; 2004 Dec; 18(4):268-73. PubMed ID: 15537997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial.
    Paoloni M; Giovannelli M; Mangone M; Leonardi L; Tavernese E; Di Pangrazio E; Bernetti A; Santilli V; Pozzilli C
    Clin Rehabil; 2013 Sep; 27(9):803-12. PubMed ID: 23543344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spasticity management in multiple sclerosis.
    Hughes C; Howard IM
    Phys Med Rehabil Clin N Am; 2013 Nov; 24(4):593-604. PubMed ID: 24314678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional outcome of intrathecal baclofen administration for severe spasticity.
    Boviatsis EJ; Kouyialis AT; Korfias S; Sakas DE
    Clin Neurol Neurosurg; 2005 Jun; 107(4):289-95. PubMed ID: 15885386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.